Incremental net monetary benefit of ocrelizumab relative to subcutaneous interferon β-1a

References

• Campbell JD, Ghushchyan V, McQueen RB, et al. Burden of multiple sclerosis on direct, indirect costs and quality of life: National US estimates. Mult Scler Relat Disord 2014;3:227-36
   PubMed Web of Science ®Google Scholar
• Lublin FD, Reingold SC. Defining the clinical course of multiple sclerosis results of an international survey. Neurology 1996;46:907-11
   PubMed Web of Science ®Google Scholar
• Vollmer T. The natural history of relapses in multiple sclerosis. J Neurol Sci 2007;256:S5-S13
   PubMed Web of Science ®Google Scholar
• Olsson T. The new era of multiple sclerosis therapy. J Intern Med 2014;275:382-6
   PubMed Web of Science ®Google Scholar
• Weinshenker BG, Bass B, Rice GPA, et al. The natural history of multiple sclerosis: a geographically based study. Brain 1989;112:133-46
   PubMed Web of Science ®Google Scholar
• Thompson A, Polman C, Miller D, et al. Primary progressive multiple sclerosis. Brain 1997;120:1085-96
   PubMed Web of Science ®Google Scholar
• Naci H, Fleurence R, Birt J, et al. Economic burden of multiple sclerosis. Pharmacoeconomics 2010;28:363-79
   PubMed Web of Science ®Google Scholar
• Weinshenker BG, Bass B, Rice G, et al. The natural history of multiple sclerosis: a geographically based study. Brain 1989;112:133-46
   PubMed Web of Science ®Google Scholar
• Mitchell AJ, Benito-León J, González J-MM, et al. Quality of life and its assessment in multiple sclerosis: integrating physical and psychological components of wellbeing. Lancet Neurol 2005;4:556-66
   PubMed Web of Science ®Google Scholar
• Buchanan R, Radin D, Chakravorty BJ, et al. Perceptions of informal care givers: health and support services provided to people with multiple sclerosis. Disabil Rehab 2010;32:500-10
   PubMed Web of Science ®Google Scholar
• Goldman DP, Joyce GF, Lawless G, et al. Benefit design and specialty drug use. Health Affairs 2006;25:1319-31
   PubMed Web of Science ®Google Scholar
• Wingerchuk DM, Lucchinetti CF, Noseworthy JH. Multiple sclerosis: current pathophysiological concepts. Lab Invest 2001;81:263-81
   PubMed Web of Science ®Google Scholar
• Miller RM, Happe LE, Meyer KL, et al. Approaches to the management of agents used for the treatment of multiple sclerosis: consensus statements from a panel of US managed care pharmacists and physicians. J Manag Care Pharm 2012;18:54-62
   PubMed Web of Science ®Google Scholar
• Goodin D, Frohman E, Garmany G, et al. Disease modifying therapies in multiple sclerosis: Subcommittee of the American Academy of Neurology and the MS Council for Clinical Practice Guidelines. Neurology 2002;58:169-78
   PubMed Web of Science ®Google Scholar
• McNamara O, Brunton L, Lazo J, et al. The pharmacological basis of therapeutics. Goodman and Gilman’s Mc Graw-Hill; 2005
   Google Scholar
• English C, Aloi JJ. New FDA-approved disease-modifying therapies for multiple sclerosis. Clin Ther 2015;37:691-715
   PubMed Web of Science ®Google Scholar
• Salter AR, Marrie RA, Agashivala N, et al. Patient perspectives on switching disease-modifying therapies in the NARCOMS registry. Patient Pref Adher 2014;8:971
   PubMed Web of Science ®Google Scholar
• Goldberg L, Edwards NC, Fincher C, et al. Comparing the cost-effectiveness of disease-modifying drugs for the first-line treatment of relapsing-remitting multiple sclerosis. J Manag Care Pharm 2009;15:543-55
   PubMed Web of Science ®Google Scholar
• Bell C, Graham J, Earnshaw S, et al. Cost-effectiveness of four immunomodulatory therapies for relapsing-remitting multiple sclerosis: a Markov model based on long-term clinical data. J Manag Care Pharm 2007;13:245-61
   PubMed Web of Science ®Google Scholar
• Noyes K, Bajorska A, Chappel A, et al. Cost-effectiveness of disease-modifying therapy for multiple sclerosis A population-based study. Neurology 2011;77:355-63
   PubMed Web of Science ®Google Scholar
• Guo S, Pelligra C, Thibault CS-L, et al. Cost-effectiveness analyses in multiple sclerosis: a review of modelling approaches. PharmacoEconomics 2014;32:559-72
   PubMed Web of Science ®Google Scholar
• Kobelt G, Berg J, Atherly D, et al. Costs and quality of life in multiple sclerosis A cross-sectional study in the United States. Neurology 2006;66:1696-702
   PubMed Web of Science ®Google Scholar
• Hauser SL, Bar-Or A, Comi G, et al. Ocrelizumab versus Interferon Beta-1a in relapsing multiple sclerosis. N Engl J Med 2017;376:221-234
   PubMed Web of Science ®Google Scholar
• Kurtzke JF. Rating neurologic impairment in multiple sclerosis an expanded disability status scale (EDSS). Neurology 1983;33:1444
   PubMed Web of Science ®Google Scholar
• Palace J, Bregenzer T, Tremlett H, et al. UK multiple sclerosis risk-sharing scheme: a new natural history dataset and an improved Markov model. BMJ Open 2014;4:e004073
   PubMed Web of Science ®Google Scholar
• Palace J, Duddy M, Bregenzer T, et al. Effectiveness and cost-effectiveness of interferon beta and glatiramer acetate in the UK Multiple Sclerosis Risk Sharing Scheme at 6 years: a clinical cohort study with natural history comparator. Lancet Neurol 2015;14:497-505
   PubMed Web of Science ®Google Scholar
• Orme M, Kerrigan J, Tyas D, et al. The effect of disease, functional status, and relapses on the utility of people with multiple sclerosis in the UK. Value Health 2007;10:54-60
   PubMed Web of Science ®Google Scholar
• Tyas D, Kerrigan J, Russell N, et al. The distribution of the cost of multiple sclerosis in the UK: how do costs vary by illness severity? Value Health 2007;10:386-9
   PubMed Web of Science ®Google Scholar
• Patzold U, Pocklington PR. Course of multiple sclerosis. Acta Neurol Scand 1982;65:248-66
   PubMed Web of Science ®Google Scholar
• Arias E. United States life tables, 2010. National vital statistics reports. Hyattsville, MD: National Center for Health Statistics. 2014;63:7
   Google Scholar
• Cutter GR, Zimmerman J, Salter AR, et al. Causes of death among persons with multiple sclerosis. Mult Scler Relat Disord 2015;4:484-90
   PubMed Web of Science ®Google Scholar
• Tappenden P, Chilcott J, O’Hagan T, et al. Cost effectiveness of beta interferons and glatiramer acetate in the management of multiple sclerosis. Final Report to the National Institute for Clinical Excellence. Centre for Bayesian Statistics in Health Economics. University of Sheffield; July 2001
   Google Scholar
• Ebers GC. Randomised double-blind placebo-controlled study of interferon β-1a in relapsing/remitting multiple sclerosis. Lancet 1998;352:1498-504
   PubMed Web of Science ®Google Scholar
• Dilokthornsakul P, Valuck RJ, Nair KV, et al. Multiple sclerosis prevalence in the United States commercially insured population. Neurology 2016;86:1014-21
   PubMed Web of Science ®Google Scholar
• U.S. Census Bureau. Current Population Survey, Annual Social and Economic Supplement. U.S. Census Bureau; 2013. Cited August 18, 2016. Available at https://www2.census.gov/programs-surveys/demo/tables/foreign-born/2013/cps2013/2013-asec-tables-nativity.pdf
   Google Scholar
• Fox RJ, Bacon TE, Chamot E, et al. Prevalence of multiple sclerosis symptoms across lifespan: data from the NARCOMS Registry. Neurodegen Dis Manag 2015;5:3-10
   PubMedGoogle Scholar
• Learmonth YC, Motl RW, Sandroff BM, et al. Validation of patient determined disease steps (PDDS) scale scores in persons with multiple sclerosis. BMC Neurol 2013;13:1
   PubMed Web of Science ®Google Scholar
• Parisé H, Laliberté F, Lefebvre P, et al. Direct and indirect cost burden associated with multiple sclerosis relapses: excess costs of persons with MS and their spouse caregivers. J Neurol Sci 2013;330:71-7
   PubMed Web of Science ®Google Scholar
• Oleen-Burkey M, Castelli-Haley J, Lage MJ, et al. Burden of a multiple sclerosis relapse. Patient–Patient-Centered Outcomes Res 2012;5:57-69
   Web of Science ®Google Scholar
• Lee S, Baxter DC, Limone B, et al. Cost-effectiveness of fingolimod versus interferon beta-1a for relapsing remitting multiple sclerosis in the United States. J Med Econ 2012;15:1088-96
   PubMedGoogle Scholar
• Truven Health Analytics Micromedex Solutions. RedBook Online. Greenwood Village, CO: Truven Health Analytics. 2016
   Google Scholar
• Federal Reserve Bank of St. Louis. Consumer Price Index for All Urban Consumers: Medical Care. Federal Reserve Bank of St. Louis, 2016 [cited April 26 2017]. Available from https://research.stlouisfed.org/fred2/series/CPIMEDSL
   Google Scholar
• Viscusi WK, Aldy JE. The value of a statistical life: a critical review of market estimates throughout the world J Risk Uncert 2003;27:5-76
   Web of Science ®Google Scholar
• Braithwaite RS, Meltzer DO, King Jr JT, et al. What does the value of modern medicine say about the $50,000 per quality-adjusted life-year decision rule? Med Care 2008;46:349-56
   PubMed Web of Science ®Google Scholar
• Weinstein MC. How much are Americans willing to pay for a quality-adjusted life year? Med Care 2008;46:343-5
   PubMed Web of Science ®Google Scholar
• Neumann PJ, Cohen JT, Weinstein MC. Updating cost-effectiveness—the curious resilience of the $50,000-per-QALY threshold. N Engl J Med 2014;371:796-7
   PubMed Web of Science ®Google Scholar
• Sachs J. Report of the Commission on Macroeconomics and Health. Macroeconomics and health: investing in health for economic development. Geneva: World Health Organization; 2001
   Google Scholar
• Grabowski DC, Lakdawalla DN, Goldman DP, et al. The large social value resulting from use of statins warrants steps to improve adherence and broaden treatment. Health Affairs 2012;31:2276-85
   Web of Science ®Google Scholar
• Jena A, Blumenthal D, Stevens W, et al. Value of improved lipid control in patients at high risk for adverse cardiac events. Am J Manag Care 2016;22:e199
   PubMed Web of Science ®Google Scholar
• Philipson T, Eber M, Lakdawalla DN, et al. An analysis of whether higher health care spending in the United States versus Europe is ‘worth it’ in the case of cancer. Health Affairs 2012;31:667-75
   Web of Science ®Google Scholar
• Hernandez L, Guo S, Kinter E, et al. Cost-effectiveness analysis of peginterferon beta-1a compared with interferon beta-1a and glatiramer acetate in the treatment of relapsing-remitting multiple sclerosis in the United States. J Med Econ 2016;19:684-95
   PubMed Web of Science ®Google Scholar
• Sanders GD, Neumann PJ, Basu A, et al. Recommendations for conduct, methodological practices, and reporting of cost-effectiveness analyses: second panel on cost-effectiveness in health and medicine. JAMA 2016;316:1093
   PubMed Web of Science ®Google Scholar
• Tremlett H, Yousefi M, Devonshire V, et al. Impact of multiple sclerosis relapses on progression diminishes with time. Neurology 2009;73:1616-23
   PubMed Web of Science ®Google Scholar
• Bruce JM, Hancock LM, Arnett P, et al. Treatment adherence in multiple sclerosis: association with emotional status, personality, and cognition. J Behav Med 2010;33:219-27
   PubMed Web of Science ®Google Scholar
• Zhornitsky S, Greenfield J, Koch MW, et al. Long-term persistence with injectable therapy in relapsing-remitting multiple sclerosis: an 18-year observational cohort study. PLoS One 2015;10:e0123824
   PubMed Web of Science ®Google Scholar
• Tappenden P, McCabe C, Chilcott J, et al. Cost‐effectiveness of disease‐modifying therapies in the management of multiple sclerosis for the Medicare population. Value Health 2009;12:657-65
   PubMed Web of Science ®Google Scholar